ENERGY-DOME/ØRSTED
27.9.2022 06:01:43 CEST | Business Wire | Press release
Energy Dome announced today a memorandum of understanding (MoU) with Ørsted, the global leader in offshore wind and a market-leading renewable energy company, to run a feasibility study on the deployment of a 20 MW / 200 MWh energy storage facility using Energy Dome’s CO2 Battery technology at one or more Ørsted sites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005112/en/
Energy Dome's CO2 Battery facility (Photo: Business Wire)
The partnership aims to use long-duration energy storage to provide baseload renewable energy to Ørsted’s end-use customers, mitigating the growing variability in energy supply, and providing grid stability services. The agreement includes an option to develop multiple additional CO2 Battery energy storage facilities, with the potential for the first 20 MW project slated to begin construction already during the second half of 2024.
The feasibility study project with Ørsted, which will dispatch renewable energy over periods of 10 hours or longer, is a milestone in Energy Dome’s roadmap on the development of multiple commercial CO2 Battery energy storage facilities. The first such site will be located in Continental Europe. This milestone follows the completion of Energy Dome’s first commercial demonstration facility in Sardinia, Italy, and the announcement of a new commercial utility-scale facility in Sardinia, under a partnership with Italian energy company A2A.
For Ørsted, testing the CO2 Battery energy storage project is part of the company’s plan to provide a comprehensive flexible solution that increases both the availability and reliability of green energy also with the aid of long duration energy storage.
Kieran White, VP Europe Onshore at Ørsted, said: “As a company focused on quickly scaling the build-out of wind, solar, Power-to-X and other renewable energy solutions, we are delighted to work with Energy Dome to explore how we can deploy their innovative long-duration energy storage technology. We consider the CO2 Battery solution to be a really promising alternative for long-duration energy storage. This technology could potentially help us decarbonise electrical grids by making renewable energy dispatchable.”
Claudio Spadacini, Founder and CEO of Energy Dome, said: “We are thrilled to collaborate with Ørsted, a clean energy pioneer and the world’s most sustainable energy company, on our shared vision of deploying as much energy storage as possible to enable 100 % renewable energy on the grid. Energy Dome looks forward to helping Ørsted achieve their renewable energy and energy storage goals as they expand into new markets.”
About Energy Dome
Energy Dome is an energy storage solution provider that is unlocking renewable energy by making solar and wind power dispatchable using the CO2 Battery. Led by a team with a track record of innovation in the energy sector, Energy Dome’s low-cost energy storage technology helps accelerate the global transition to renewable energy by enabling greater penetration of renewables on the grid. Energy Dome is currently starting construction on another 20 MW/200 MWh energy storage facility in Sardinia, Italy, in partnership with A2A and is developing a pipeline of projects in Europe, the U.S. and other regions around the world. For more information, please visit www.energydome.com.
About Ørsted
The Ørsted vision is a world that runs entirely on green energy. Ørsted develops, constructs, and operates offshore and onshore wind farms, solar farms, energy storage facilities, renewable hydrogen and green fuels facilities, and bioenergy plants. Moreover, Ørsted provides energy products to its customers. Ørsted is the only energy company in the world with a science-based net-zero emissions target as validated by the Science Based Targets initiative (SBTi), and Ørsted aims to deliver a net-positive biodiversity impact from all new renewable energy projects it commissions from 2030 at the latest. Ørsted ranks as the world’s most sustainable energy company in Corporate Knights' 2022 index of the Global 100 most sustainable corporations in the world and is recognised on the CDP Climate Change A List as a global leader on climate action. Headquartered in Denmark, Ørsted employs 7,016 people. Ørsted's shares are listed on Nasdaq Copenhagen (Ørsted). In 2021, the group's revenue was DKK 77.7 billion (EUR 10.4 billion). Visit Ørsted.com or follow us on Facebook, LinkedIn, Instagram, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom